Innocens raises €1.5 million to enhance neonatal monitoring technology aimed at predicting life-threatening infections in premature infants.

Information on the Target

Innocens is a pioneering startup founded by neonatologist David Van Laere, emerging as a prominent player in the neonatal care sector. The company's mission is to enhance the monitoring of premature infants and to predict life-threatening infections through advanced digital technology. The recent funding of €1.5 million will support Innocens in its endeavor to commercialize its innovative solutions and extend its societal impact across Europe.

The company developed a sophisticated digital assistant that employs an advanced algorithm to analyze the monitoring data of premature babies. This system aims to proactively identify signs of infections, specifically sepsis, which poses a significant risk to vulnerable infants. Innocens is focused on achieving clinical validation and regulatory certification for its product to ensure broad market adoption.

Industry Overview in Belgium

In Belgium, approximately 7% of all births result in premature delivery, often necessitating specialized care in neonatal intensive care units (NICUs). Premature infants are particularly susceptible to infection